Metabolički sindrom i restenoza karotidne arterije

Kylin E. Studien iiber das Hypertonie-Hyperglykamie-Hyperurikamiesyndrome. Zentralblatt Für Innere Medizin 1923; 44: 105−27.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595−607.

Ferannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317(6): 350−7.

Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and clasiffication of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539−53.

Third Report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002; 106(25): 3143−421.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabol-ic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17): 2735–52.

Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Con-sensus Group. The metabolic syndrome: a new world-wide defi-nition from the International Diabetes Federation consensus. Lancet 2005, 366(9491):1059–62.

Maksimovic MZ, Vlajinac HD, Radak DJ, Marinkovic JM, Jorga JB. Prevalence of the metabolic syndrome in patients with carotid disease according to NHLBI/AHA and IDF criteria: a cross-sectional study. BMC Cardiovasc Disord 2012; 12: 2.

Lakka HM, Laksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002; 288(21): 2709−16.

Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; (13): 1−7.

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3): 391−7.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356−9.

Jorga J, Šević Lj, Maksimović M, Durišić N, Davidović D, Micić D. Relationship between C-reactive protein and the metabolic syndrome in overweight and obese patients. Obesity Metabol-ism 2007; 3(4): 161−7.

Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004; 173(2): 363−9.

Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Vis-seren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneu-rysm. Eur Heart J 2004; 25(4): 342−8.

Maksimovic M, Vlajinac H, Radak Dj, Maksimovic J, Otasevic P, Marinković J, et al. Frequency and Characteristics of Metabolic Syndrome in Patients with Symptomatic Carotid Atherosclero-sis. Rev Med Chil 2009; 137(3): 329−36.

Maksimovic M, Vlajinac H, Radak D, Marinkovic J, Jorga J. Rela-tionship between peripheral arterial disease and metabolic syn-drome. Angiology 2009; 60(5): 546−53.

Halliday A, Mansfield A, Marro J, Petto C, Petto R, Potter J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symp-toms: randomised controlled trial. Lancet 2004; 363(9420): 1491−502.

Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe disease. N Engl J Med 1998; 12: 339(20): 1415−25.

Alamowitch S, Eliasziw M, Algra A, Meldrum H, Barnett HJ. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001; 357(9263): 1154−60.

National Center for Health Statistics, US Department of Health and Human Services. National Hospital Discharge Sur-vey: 2003. Available from: www.cdc.gov/nchs/data/series/sr_13/sr13_160.pdf

Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. J Am Med Assoc 1995; 273(18): 1421–8.

Radak DJ, Tanaskovic S, Ilijevski NS, Davidovic L, Kolar J, Radak S, et al. Eversion carotid endarterectomy versus best medical treatment in symptomatic patients with near total internal ca-rotid occlusion: a prospective nonrandomized trial. Ann Vasc Surg 2010; 24(2): 185−9.

Lattimer CR, Burnand KG. Recurrent carotid stenosis after CEA. Br J Surg 1997; 84(9): 1206−19.

Liapis CD, Kakisis JD, Papavassiliou VG, Koumakis KM, Gogas JG. Risk Factors Associated with Recurrent Carotid Artery Stenosis. Vasc Endovascular Surg 1999; 33(6); 697−704.

Fluri F, Engelter ST, Wasner M, Stierli P, Merlo A, Lyrer AP. The probability of restenosis, contralateral disease progression, and late neurologic events following carotid endarterectomy: A long-term follow-up study. Cerebrovasc Dis 2008; 26(6): 654–8.

Moore WS, Kempczinski RF, Nelson J, Toole JF. Recurrent carotid stenosis: results of the ACAS. Stroke 1998; 29(10): 2018−25.

Reina-Gutierrez T, Serrano-Hernando FJ, Sanchez-Hervas L, Ponce A, Vega de CM, Martin A. Recurrent carotid artery stenosis fol-lowing endarterectomy: natural history and risk factors. Eur J Vasc Endovasc Surg 2005; 29(4): 334–41.

Ballotta E, Dagiau G, Piccoli A, Baracchini C. Durability of carotid endarterectomy for treatment of symptomatic and asympto-matic stenosis. J Vasc Surg 2004; 40(2): 270−8.

Ballotta E, Da GG, Meneghetti G, Liapis CD, Kakisis JD, Kostakis AG. Recurrent carotid artery stenosis: natural history and pre-disposing factors. A long-term follow-up study. Int Angiol 2001; 20(4): 330–6.

Ballotta E, Da GG, Meneghetti G, Barbon B, Militello C, Baracchini C. Progression of atherosclerosis in asymptomatic carotid arteries after contralateral endarterectomy: a 10-year prospective study. J Vasc Surg 2007; 45(3): 516−22.

Volteas N, Labropoulos N, Leon M, Kalodiki E, Chan P, Nicolaides AN. Risk factors associated with recurrent carotid stenosis. Int Angiol 1994; 13(2): 143−7.

Rapp JH, Qvarfordt P, Krupski WC, Ehrenfeld WK, Stoney RJ. Hypercholesterolemia and early restenosis after carotid endar-terectomy. Surgery 1987; 101(3): 277−82.

Strineka M, Lovrencic-Huzjan A, Vukovic V, Ažman D, Bene R, Lovricevic I, et al. Development of postoperative internal carotid artery occlusion due to the presence of risk factors. Acta Clin Croat 2009; 48(3): 247−51.

Fluri F, Hatz F, Voss B, Lyrer PA, Engelter TS. Restenosis after carotid endarterectomy: significance of newly acquired risk fac-tors. Eur J Neurol 2010; 17(3): 493−8.

Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parenteral effects. Diabetes 1996; 45(11): 1585−93.

Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001; 24(4): 683–9.

Protack CD, Bakken AM, Xu J, Saad WA, Lumsden AB, Davies MG. Metabolic syndrome: A predictor of adverse outcomes after carotid revascularization. J Vasc Surg 2009; 49(5): 1172−80.